{"id":"0ea6132f5135","type":"article","url":"https://hartvaat.nl/2026/03/01/optimalisatie-van-caart-voor-wisselende-antilichaamlandschappen/","title":"Optimalisatie van CAART voor wisselende antilichaamlandschappen","title_en":"Optimizing CAART for evolving antibody landscapes","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["pelacarsen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01002-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01002-6/fulltext","authors":["Man Sun","Dan Zang","Jun Chen"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This commentary discusses the preclinical validation of chimeric autoantibody receptor T cells targeting the PLA2 receptor in membranous nephropathy, with considerations for adapting this precision immunotherapy approach to evolving antibody profiles.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Commentaar op de preklinische validatie van chimere auto-antilichaamreceptor T-cellen (CAARTs) gericht tegen de PLA2-receptor bij membraneuze nefropathie, met overwegingen over het aanpassen van de aanpak aan wisselende antilichaamprofielen.","abstract_original":"We read with great interest the article by Altun et al.,1 which presents an elegant preclinical validation of chimeric autoantibody receptor T cells (CAARTs) targeting the phospholipase A2 receptor (PLA2R) in membranous nephropathy. By demonstrating high antigen specificity and a favorable safety profile through B-cell receptor recognition and cytolytic targeting of autoreactive B-cell clones, this study marks a significant step toward precision B-cell immunotherapy for PLA2R-associated membranous nephropathy."}